The Use Of Surrogate Endpoints In Cll Clinical Trials

Using Surrogate Markers in Clinical Trials for CLL (Chronic Lymphocytic Leukemia)

Use of Surrogate Endpoints in Oncology

endpoints, clinical trial outcomes, & surrogate endpoints

Lecture Medical Oncology - Endpoints in clinical trials

European Association of Urology

Surrogate Endpoints for New Drug Discovery in Acute Lymphoblastic Leukemia

SURROGATE ENDPOINTS in Clinical Trials I Clinical Research

SIRO Clinical Research Insitute

Minimal Residual Disease as a Surrogate Endpoint in Hematologic Cancer Trials: Session 2

Biomarkers and Surrogate Endpoints in Drug Development

Lecture 2 - Surrogate Endpoints in Oncology - Reading and Interpreting Cancer Trials

Vinay Prasad MD MPH

Statistical Considerations on the Use of Surrogate Endpoints | Thomas Fleming

Arthritis Foundation

Segment 5 - Surrogate End Points in Clinical Trials: The Right Information?

What are the surrogate endpoints in AML?

Minimal Residual Disease as a Surrogate Endpoint in Hematologic Cancer Trials: Session 3

Surrogate endpoint biomarkers in research

Minimal Residual Disease as a Surrogate Endpoint in Hematologic Cancer Trials: Session 1

Using MRD as an endpoint in clinical trials

VJHemOnc – Video Journal of Hematology & HemOnc

Minimal Residual Disease as a Surrogate Endpoint in Hematologic Cancer Trials: Session 4

Value of MRD measurement in CLL

VJHemOnc – Video Journal of Hematology & HemOnc

CLL Clinical Trials Explained

Patient Empowerment Network

Health Plan Take on the Cancer Drug Approval Process and Surrogate Endpoints